Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 10/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.53 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | CDC25B | P30305 | 8/20 | 0.52 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.52 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.52 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.52 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.52 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.52 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.50 |
| ▸ | GJB2 | P29033 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14416244 | 0.91 | PTPN1 (0.49) | PTPN1PTPN2PTPN11NT5ECDC25B | |
| SCHEMBL8723384 | 0.91 | HTR1A (0.52) | PTPN1PTPN2PTPN11NT5ECDC25B | |
| SCHEMBL21657199 | 0.91 | HTR1A (0.52) | PTPN1PTPN2PTPN11NT5ECDC25B | |
| SCHEMBL28943950 | 0.91 | HTR1A (0.52) | PTPN1PTPN2PTPN11NT5ECDC25B | |
| SCHEMBL11311474 | 0.91 | SLC6A2 (0.53) | PTPN1PTPN2PTPN11NT5ECDC25B | |
| SCHEMBL1775656 | 0.90 | PTPN1 (0.48) | PTPN1PTPN2PTPN11NT5ECDC25B | |
| SCHEMBL1776554 | 0.90 | PTPN1 (0.48) | PTPN1PTPN2PTPN11NT5ECDC25B | |
| SCHEMBL1775653 | 0.90 | PTPN1 (0.48) | PTPN1PTPN2PTPN11NT5ECDC25B | |
| SCHEMBL10408745 | 0.89 | HTR1A (0.53) | PTPN1PTPN2PTPN11NT5ECDC25B | |
| SCHEMBL10408744 | 0.89 | HTR1A (0.53) | PTPN1PTPN2PTPN11NT5ECDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275524-A1 | NOVEL HYPOCHOLESTEROLEMIC COMPOUNDS | LIPIDEON BIOTECHNOLOGY AG | 2009-11-05 | — | — | US | disclosed |
| US-7544667-B2 | Hypocholesterolemic compounds | LIPIDEON BIOTECHNOLOGY AG (CH) | 2009-06-09 | — | — | US | disclosed |
| US-20070275909-A1 | Useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels; carbohydrate-containing pyrazolidinone or oxazolidinone derivatives, for example | LIPIDEON BIOTECHNOLOGY AG (CH) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275524-A1 | NOVEL HYPOCHOLESTEROLEMIC COMPOUNDS | CYP46A1, SREBF1, CETP | PTPN1 2454/4885PTPN2 2284/4885PTPN11 1855/4885 |
| US-20070275909-A1 | Useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels; carbohydrate-containing pyrazolidinone or oxazolidinone derivatives, for example | PCSK9, APOB, HMGCR | PTPN1 1784/4885PTPN2 2127/4885PTPN11 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.